<DOC>
	<DOCNO>NCT02709005</DOCNO>
	<brief_summary>This Phase II , Double-Blind , Randomized , Placebo-Controlled , Multi-center Trial enrol 120 subject Bacterial Vaginosis randomize ratio 2:1 receive active test article ( 5 % Monolaurin Vaginal Gel ) placebo ( vehicle ) . The primary objective ass safety tolerability 5 % Monolaurin Vaginal Gel compare vehicle placebo gel ( excipients ) assess efficacy clinical cure rate 5 % Monolaurin Vaginal Gel compare vehicle placebo gel Visit 2 .</brief_summary>
	<brief_title>Safety Efficacy 5 % Monolaurin Vaginal Gel Administered Intravaginally Treatment Bacterial Vaginosis</brief_title>
	<detailed_description>Bacterial vaginosis ( BV ) disease vagina cause bacteria . The common symptom BV abnormal homogeneous off-white vaginal discharge ( especially sex ) unpleasant smell . This Phase II , Double-Blind , Randomized , Placebo-Controlled , Multi-center Trial enrol 120 woman , 18-50 year old , clinical evidence bacterial vaginosis . Subjects randomize ratio 2:1 receive active test article ( 5 % Monolaurin Vaginal Gel ) placebo ( vehicle ) outpatient therapy . Subjects stratify first time episode bacterial vaginosis recurrent bacterial vaginosis . The primary objective study : 1 ) To assess safety tolerability 5 % Monolaurin Vaginal Gel compare Vehicle Placebo Gel ( excipients ) 2 ) To assess efficacy clinical cure rate 5 % Monolaurin Vaginal Gel compare Vehicle Placebo Gel Visit 2 . The secondary objective : 1 ) To evaluate therapeutic cure rate 5 % Monolaurin Vaginal Gel compare Vehicle Placebo Gel Visits 2 3 , 2 ) To evaluate clinical cure rate 5 % Monolaurin Vaginal Gel compare Vehicle Placebo Gel Visit 3 , 3 ) To evaluate change Nugent 's criterion vaginal bacterial flora Visits 2 3 . This study expect last 13 month , subject participation duration 4 week .</detailed_description>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Monolaurin</mesh_term>
	<criteria>Nonpregnant female age 18 50 year , inclusive . Women childbearing potential ( surgically sterile via tubal ligation , bilateral oophorectomy hysterectomy postmenopausal &gt; /=1 year ) must agree practice reliable contraception 28day period enrollment 30 day follow treatment . Note : Acceptable birth control method purpose study may include , limited , abstinence intercourse male partner , monogamous relationship vasectomize partner , barrier method include condom diaphragm , intrauterine device , license hormonal method . NuvaRing contraceptive use prohibit study since device alter vaginal secretion . Presenting sign bacterial vaginosis ( per Amsel Criteria ) . Subjects must meet three four criterion enrollment : presence discharge , great equal 20 % clue cell wet prep , positive `` whiff test '' KOH prep , vaginal pH great 4.5 Not currently menstruate expect next 4 day . Able understand comply plan study procedure . Willing abstain sexual intercourse , insertion tampon , douche intravaginal medication object Visit 1 Visit 2 48 hour prior Visit 3 . Provide write informed consent initiation study procedure available study visit . No known history HIV . Subjects age 21 must report normal PAP smear within past three year . Signs symptom vaginal/cervical/pelvic infection screen clinical diagnosis vaginal/cervical/pelvic infection past 14 day . * ( include limit yeast vulvovaginitis , chlamydia , gonorrhea , trichomonas , genital ulcer disease , pelvic inflammatory disease ) . Selftreatment presume yeast vaginitis exclusion treatment discontinue 14 day great prior enrollment . Treatment BV within past 14 day . Vaginal/cervical dysplasia cervical HPV relate disease past year . Subject report 6 episode vaginitis within past year . History undiagnosed vaginal bleeding . Use systemic , vaginal , perineal antibiotic within 2 week prior enrollment study . Use immunosuppressive immunomodulatory drug ( &gt; 0.5 mg/kg/day &gt; /=20 mg total dose/day prednisone orally &gt; 800 mcg inhale beclomethasone ) 2 consecutive week within 6 month prior enrollment ( nasal nongenital topical steroid allow ) . History allergic reaction attribute compound similar chemical biologic composition Monolaurin vaginal gel . Uncontrolled concurrent illness include , limited , ongoing active infection , active liver , kidney autoimmune disease , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Note : Subjects diabetes history organ marrow transplant exclude . A history thyroid disease permit long thyroid disease stable . Acute illness within 3 day receipt study product . Pregnant woman woman plan become pregnant within 30 day final study dose , woman breastfeed . Immunosuppression result underlie illness treatment use anticancer chemotherapy radiation therapy ( cytotoxic ) within precede 36 month . Active neoplastic disease ( exclude nonmelanoma skin cancer ) history hematologic malignancy . Active neoplastic disease define neoplastic disease treatment neoplastic disease within past 5 year . Received experimental agent ( vaccine , drug , biologic , device , blood product , medication ) within 30 day receipt study product expect receive experimental agent 1 month study period . Any condition would place subject unacceptable risk injury , render unable meet requirement protocol , may interfere successful completion study . A history alcohol drug abuse previous 1 year opinion site investigator would interfere study procedure . Note : For example , daily excessive alcohol use frequent binge drinking determine investigator , daily marijuana use .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 4, 2017</verification_date>
	<keyword>Bacterial Vaginosis</keyword>
	<keyword>Monolaurin Vaginal Gel</keyword>
</DOC>